CQN-THE-GENEVA-ASSOC.
6.3.2017 16:45:15 CET | Business Wire | Press release
First paragraph, second sentence of release, the date should be 9th March 2017 instead of 8th March 2017.
The corrected release reads:
THE GENEVA ASSOCIATION: HOW WILL RISK MODELLING SHAPE THE FUTURE OF RISK TRANSFER? GLOBAL EXPERTS LEAD THE WAY
Leading think tank of the international insurance industry, The Geneva Association, welcomes top international experts to discuss and explore the issue – “How Will Risk Modelling Shape the Future of Risk Transfer?” This scientific seminar is co-organised with the SCOR Foundation and hosted at the SCOR Paris headquarters on 9th March 2017. It will inform a ground-breaking research report by The Geneva Association’s Extreme Events and Climate Risk Research Programme, publishing in June 2017.
The last three and a half decades have witnessed a general trend of rising economic losses associated with extreme events. This is due to multiple factors, including increased concentration of people and assets in exposed areas such as coastal regions, poor development planning and related practices, highly sophisticated but vulnerable global production processes and the increasing severity and frequency of extreme weather-related events linked to a changing climate.
Risk analysis is the foundation for informed decision-making, increasing the understanding of the characteristics of risk, supporting risk pricing, and evaluating cost–benefits of various risk management strategies. In the mid-1980s and early 1990s, a number of major catastrophes in North America and Europe led to unprecedented high losses, resulting in insolvencies and/or bankruptcies in the insurance sector, and pointing to the need for a more rigorous and quantifiable approach to assessing and underwriting risks.
The development and utilization of catastrophe risk models (cat models) over the last 25 years has revolutionized the (re)insurance industry’s approach to pricing, underwriting and managing their complex risk portfolios. Beyond the insurance sector, the international development community has also adopted these models to help governments better understand risk and make risk-based decisions, helping improve disaster and climate risk management decisions.
The seminar brings together leading international experts from the (re)insurance industry, risk modelling community, international organizations, international donors, governments and the scientific community to share experiences and explore opportunities for strengthened cooperation and partnerships. The programme will examine the following critical issues:
(i) Enhancing current cat models – building on lessons learned from their development and utilization over the last 25 years;
(ii) Finding effective pathways to expand risk information and cat risk modelling tools to support public-sector decisions; and,
(iii) Harnessing the latest scientific and technological developments for a new generation of forward-looking risk models.
Dr. Maryam Golnaraghi, Director of the Extreme Events and Climate Risks Research Programme at The Geneva Association, said: “As one of its top priorities, The Geneva Association is convening a diverse group of leading experts in the industry, cat modelling, and various areas of science and technology to explore how risk modelling can shape the future of risk transfer around the world. Specifically, we are not only exploring opportunities to enhance current cat modelling approaches, but also opportunities for harnessing scientific and technological advancements in areas such as environmental surveillance, climate monitoring and forecasting, engineering, big data, and artificial intelligence for development of the new generation of systems-based risk models that can innovate risk transfer.”
Anna Maria D’Hulster, Secretary General of the Geneva Association said, “The insurance industry has deep risk knowledge and is working at the forefront of risk assessment, risk pricing and risk transfer. Public-private partnerships could be instrumental in helping the public sector in developing risk-informed preventive measures and risk transfer programmes that help government, businesses and individuals with managing their risks.”
ENDS
Notes to Editors
The Geneva Association is the leading international insurance think tank for strategically important insurance and risk management issues. It is a unique platform for dialogue between leaders of the insurance industry and key decision-makers at the international and national levels to evidence the important social and economic role of the insurance industry.
The Geneva Association identifies fundamental trends and strategic issues where insurance plays a substantial role or which influence the insurance sector. Through the development of research programmes, regular publications and the organisation of international meetings, The Geneva Association serves as a catalyst for progress in the understanding of risk and insurance matters and acts as an information creator and disseminator.
The Geneva Association membership comprises a statutory maximum of 90 chief executive officers (CEOs) from the world’s top insurance and reinsurance companies. It organises international expert networks and manages discussion platforms for senior insurance executives and specialists as well as policy-makers, regulators and multilateral organisations.
Established in 1973, The Geneva Association, officially the “International Association for the Study of Insurance Economics”, is based in Zurich, Switzerland and is a non-profit organisation funded by its membership.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005789/en/
Contact:
The Geneva Association
Isabel Barratt
Communications
Manager
+41 44 200 49 96
isabel_barratt@genevaassociation.org
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
